C

CSL

Develops and delivers biotherapies and vaccines

Global Procurement, Logistics & Warehousing Director

Full-TimePosted on 10/21/2026
No salary listed
Expert
Bachelor's, MBA
Opfikon, Switzerland+2 moreMore locations: Maidenhead, UK | Bern, Switzerland
In PersonTravel 10–30% domestically and internationally as required.
Operations & LogisticsProcurement & Sourcing

About the job

Requirements
  • A bachelor's degree in Supply Chain Management or a related field is preferred.
  • Experience with logistics categories is highly preferred.
  • A postgraduate business degree or MBA is highly regarded.
  • At least 10 years of experience in strategic sourcing or relevant experience is required.
  • Leadership experience leading a global team is required.
  • A deep understanding of logistics and warehousing categories is required.
  • The ability to develop appropriate sourcing strategies is required.
  • Understanding of the pharmaceutical industry or a related industry is preferred but not essential.
  • Incorporates external factors into business strategy.
  • Empowers a One-CSL team approach.
  • Creates an environment of decision-making and appropriate risk-taking.
  • Creates a nimble environment.
  • Drives the strategy throughout the organization.
  • Takes proactive steps to secure future talent.
  • Strategic orientation, inquisitiveness, comfort with ambiguity, and self-motivation to identify trends and improvement opportunities aligned with business objectives and strategic plans are required.
  • Strong executive presence, demonstrated leadership and collaboration skills, and the ability to build effective relationships and influence peers and key stakeholders are required.
  • Demonstrated strength and ability to organize and lead multiple dynamic and cohesive teams concurrently are required.
  • Strong project management skills are required, including planning tasks, assigning resources, managing progress, removing barriers, managing change, resolving conflict, building consensus, and motivating team members across multiple concurrent projects.
  • Excellent verbal and written communication skills are required, including tailoring messages to the audience, presenting information clearly and concisely, applying creative approaches to engage audiences, managing change, resolving conflict, and building consensus.
  • Strong knowledge of category management, strategic sourcing, and supplier relationship management is required.
  • The ability to build and maintain strong relationships and collaborate effectively across all levels and functions is required.
Responsibilities
  • Develop annual and long-term plans for relevant logistics and warehousing categories aligned with procurement and business strategies, establishing clear goals and action plans for global category management leads to reduce total cost of ownership and risk while increasing innovation, customer service, compliance, and quality.
  • Develop strategies and ensure operational excellence across logistics and warehousing categories, including third- and fourth-party logistics warehousing, air and sea freight, freight packaging equipment, road freight, courier services, and global trade compliance.
  • Influence and drive year-over-year cost savings while developing innovative strategies to make CSL a best-in-class financially managed organization.
  • Independently develop complex strategies for supplier consolidation, segmentation, and best-in-class supply management processes for key logistics and warehousing suppliers.
  • Influence key stakeholders to drive continuous improvement, reduce waste, and eliminate redundancies across the logistics portfolio.
  • Develop, implement, and manage global logistics and warehousing strategies.
  • Act as a strategic business partner to CSL logistics and supply chain organizations.
  • Interact regularly with supply chain senior leadership.
  • Support organizational integration activities and identify synergies.
  • Participate actively in Enterprise Procurement and Supplier Management Leadership Team engagements and meetings.
  • Drive value across complex categories by ensuring all global category leads have effective category management strategies, and establish and manage councils for business-critical commodities aligned with evolving business requirements to deliver lower cost of ownership, lower risk, higher quality, and better performance.
  • Lead complex and business-critical negotiations with key suppliers and coach sourcing organizations in negotiations.
  • Ensure CSL sourcing conducts business with integrity and in compliance with applicable laws, regulations, anti-bribery requirements, and the CSL's ethical standards, and promote diversity and inclusion through utilization of small, disadvantaged, and diverse suppliers.
  • Establish and oversee supplier relationship management processes with critical global suppliers, including risk management strategies following global policies and supplier segmentation, to enhance relationships and innovation while assuring supply, quality, service, and continuous improvement and minimizing costs; develop processes to measure value beyond savings in line with longer-term plans and objectives.
  • Implement global procedures to ensure sourcing activities comply with the CSL Sourcing Policy, Code of Responsible Business Practices, and other compliance standards.
  • Oversee and ensure achievement of supply performance key performance indicators, and ensure category leads and managers conduct regular operational reviews under procurement governance processes, supported by analysis and reporting from the Centre of Excellence.
  • Build and maintain effective professional relationships with global senior executive internal stakeholders and senior executives of major suppliers through ongoing discussions and participation in formal teams and groups, to deliver procurement goals and manage supplier performance, issues, procurement improvement initiatives, and broader business issues.
  • Lead, motivate, and develop procurement employees, including long-term talent development, succession planning, and performance management, supporting employees to meet or exceed performance expectations while demonstrating CSL values.
  • Lead and contribute to complex global transformation projects and continuous improvement initiatives as needed to deliver targeted benefits.
Desired Qualifications
  • Understanding of the pharmaceutical industry or a related industry.

About the company

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CSL reported US$176 million FY26 cost savings, ahead of its transformation target.
  • US military flu-vaccine exceptions restored some demand after April 2026 mandate cuts.
  • VarmX’s 2029 coagulation program gives CSL a new high-value pipeline beyond plasma.

What critics are saying

  • FY26 statutory loss hit US$2.6 billion after US$7.1 billion impairments and restructuring.
  • CSL plans US$400 million FY27 savings, implying more closures, layoffs, and execution friction.
  • The U.S. plasma turnaround depends on Horizon 2; failure risks long-term margin collapse.

What makes CSL unique

  • CSL’s FY26 revenue reached US$15.8 billion across plasma, vaccines, and Vifor.
  • Seqirus’ AUJEMFLU won UK and European approvals, backed by Lancet Phase 3 data.
  • HEMGENIX remains Europe’s first approved hemophilia B gene therapy, strengthening CSL Behring.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
PR Newswire
Oct 21st, 2026
CSL appoints ViiV Healthcare chief Deborah Waterhouse as CEO on $1.9M base salary

CSL Limited has appointed Deborah Waterhouse as chief executive officer and managing director, effective February 1, 2027. The board's decision followed a global search and was unanimous. Waterhouse has led ViiV Healthcare, an HIV specialist majority owned by GSK, since 2017. ViiV had sales of £7.7 billion in GSK's 2025 financial year. She also serves as president of GSK Global Health and previously ran GSK's US vaccines and primary care businesses. Her base salary will be £1,500,000 a year. She will stay based in the UK. Gordon Naylor will remain interim chief executive until then, before returning to the board as a non-executive director.

Yahoo Finance
Oct 8th, 2026
CSL to roll out Haemonetics' NexSys devices across all US plasma centres by end of 2027

Haemonetics shares jumped 12% after the company announced CSL now expects to move all of its current US plasma collection centres to Haemonetics' NexSys devices by the end of 2027. The deal, first disclosed in August, was initially limited to only a portion of CSL's US centres with no timeline. The expanded agreement is significant because losing CSL previously flattened Haemonetics' growth. In fiscal 2026, the company's organic revenue growth was just 1.1%, compared to 9.5% excluding lost CSL sales. Following the surge, Haemonetics trades at approximately 21 times forward earnings, above its five-year average of 19.1 times. The deal is non-exclusive with no minimum purchase requirements, meaning CSL can still modify scope and timing. Management plans to provide further details during its November earnings call.

Pharma Dispatch
Oct 6th, 2026
CSL raises $1.5B from US bond investors to refinance debt

CSL has raised US$1.5 billion through corporate bonds issued in the United States to refinance existing debt. The Australian biotechnology company turned to offshore debt markets for the transaction. The bond issuance allows CSL to manage its capital structure by replacing current borrowings with new financing secured from US investors.

CSL
Sep 21st, 2026
CSL partners with VarmX in a strategic collaboration and option agreement to develop first-in-class investigational coagulation treatment

Melbourne, Australia – 16 September 2025 CSL today announced it has entered into a strategic collaboration with privately held Dutch biotech company VarmX BV to support the company’s...

PR Newswire
Sep 10th, 2026
CSL Seqirus' triple-enhanced flu vaccine shows superior protection for older adults in Lancet study

CSL Seqirus has published Phase 3 study results in The Lancet Infectious Diseases for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine for older adults. The vaccine, marketed as AUJEMFLU, combines three proven approaches: MF59 adjuvant, cell-based manufacturing, and higher-dose formulation. The randomised study enrolled 7,699 adults aged 50 and older across eight countries. Results demonstrated superiority versus an adjuvanted egg-based comparator across all four influenza strains and age groups. The vaccine showed non-inferiority versus a recombinant vaccine for three of four strains in the 50-plus age group and all four strains in those aged 65-plus. The trivalent formulation received approval from the UK's MHRA and the European Commission earlier this year for adults aged 50 and above. Regulatory submissions have been made in multiple markets.